PACKAGE LEAFLET: INFORMATION FOR THE USER

Additrace® N concentrate for solution for infusion

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

What is in this leaflet

- 1. What Additrace N is and what it is used for
- 2. What you need to know before you receive Additrace N
- 3. How you are given Additrace N
- 4. Possible side effects
- 5. How to store Additrace N
- 6. Contents of the pack and other information

1. What Additrace N is and what it is used for

Additrace N is a medicine that contains trace elements. Trace elements are tiny amounts of chemicals that your body needs to work normally. Additrace N is given intravenously (into a vein) when you cannot eat normally. This medicine is usually used as part of a balanced intravenous diet, together with proteins, fat, carbohydrates, salts and vitamins.

2. What you need to know before you receive Additrace N

You should not receive Additrace N:

- if you are allergic (hypersensitive) to any of the ingredients of this medicine (listed in section 6). If you develop a rash or other allergic reactions (like itching, swollen lips or face, or shortness of breath), inform your doctor immediately.

Warnings and precautions

Talk to your doctor if you have problems with the way your liver and/or kidney work. Your doctor may want to do regular blood tests to check your condition.

Other medicines and Additrace N

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

Driving and using machines

Additrace N has no effect on driving or using machines.

3. How you are given Additrace N

This medicine will be administered to you by a healthcare professional.

You will receive your medicine by infusion (IV drip), directly into a vein. Your doctor will decide on the correct dose for you to receive.

The recommended dose for adults is 10 millilitres (ml) each day.

Additrace N should be added to another solution before it is given to you. Your doctor or nurse will make sure it is prepared correctly before you receive Additrace N.

Use in children

Additrace N is not recommended for use in children weighing less than 40 kilograms body weight.

If you receive too much Additrace N

It is very unlikely that you will receive more medicine than you should as your doctor or nurse will monitor you during the treatment. However if you think that you have received too much Additrace N, inform your doctor or nurse immediately.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

No known undesirable effects have been reported with the use of Additrace N.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance. Website: www.hpra.ie.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Additrace N

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and vial label. The expiry date refers to the last day of that month.

Do not use this medicine if you notice Additrace N is cloudy or contains sediment. This medicine does not require any special storage conditions.

Your doctor and hospital pharmacist are responsible for the correct storage, use and disposal of Additrace N infusion.

After dilution: The addition of Additrace N should be performed immediately before the start of the infusion and should be used within 24 hours. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and

would normally not be longer than 24 hours at 2-8°C, unless mixing has taken place in controlled and validated aseptic conditions.

Any solution remaining after treatment should be thrown away via approved hospital procedures.

6. Contents of the pack and other information

What Additrace N concentrate for solution for infusion contains

The active substances in one ampoule (10 ml) are:

Chromic chloride hexahydrate
Copper chloride dihydrate
Ferric chloride hexahydrate

53.3 micrograms
1.02 milligrams
5.40 milligrams

Manganese chloride tetrahydrate
Potassium iodide
Sodium fluoride
Sodium molybdate dihydrate
Sodium selenite anhydrous
Zinc chloride

198 micrograms
2.10 milligrams
48.5 micrograms
173 micrograms
10.5 milligrams

The active ingredients in 10 ml of Additrace N correspond to:

Cr	0.2 μmol	¹ 10 μg
Cu	6 μmol	380 µg
Fe	20 μmol	1.1 mg
Mn	1 µmol	55 μg
I	1 jumol	130 µg
F	50 μmol	950 ug
Mo	0.2 μmol	19 μg (as Mo ⁶⁺) 79 μg (as Se ⁴⁺)
Se Zn	1 μmol	$79 \mu g (as Se^{4+})$
Zn	77 μmol	5 mg

The content of sodium and potassium in 10 ml corresponds to:

Sodium	1.0 mg	52 µmol
Potassium	39 μg	1 µmol

- The other ingredients are: Xylitol, Hydrochloric acid, concentrated (for pH adjustment), Water for injections.

What Additrace N concentrate for solution for infusion looks like and contents of the pack

Additrace N is a clear, almost colourless solution of trace elements.

Additrace N is available in a polypropylene ampoule containing 10 ml of concentrate, in the following pack size: $20 \times 10 \text{ ml}$

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Fresenius Kabi Deutschland GmbH Else-Kröner-Straße 1, 61352 Bad Homburg v.d.Höhe Germany

Manufacturer

HP Halden Pharma AS Svinesundsveien 80 1788 Halden, Norway

This leaflet was last revised in March 2024.